Clinically, SGLT2 inhibitors lower albuminuria by 15% (6% to 23%, 95% CI) in non‐diabetic CKD within the first 2 weeks and persists up to 3 years of follow‐up (Jongs et al., 2021). The gene discussed is SLC5A2; the disease is chronic kidney disease.